EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome
Medicine should no longer be used for other disorders of the gut
A review by the European Medicines Agency (EMA) has concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults. However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders, a group of disorders with a variety of causes that may require different treatment approaches.
Symbioflor 2, which contains Escherichia coli bacteria, has been described as a probiotic, which means that it encourages the growth of beneficial organisms (‘flora’) in the gut. It was first made available in Germany in the 1950s and subsequently in Austria and Hungary.
In reaching its conclusions, EMA’s Committee for Medicinal Products for Human Use(CHMP) reviewed all available evidence on the effectiveness and safety of Symbioflor 2. The data included clinical studies, scientific publications, post-marketing experience, as well as information provided by the company and the views of an expert group formed for evaluating Symbioflor 2. The review did not find any new evidence on the effectiveness of Symbioflor 2 since the product was last approved. Available evidence suggests that the risk of harm from Symbioflor 2 is low.
A randomised study involving around 300 adults suggested that Symbioflor 2 was effective for treating IBS. However, the study had weaknesses. Benefit has not yet been established in children with IBS.
Since the available data are not sufficiently robust for the CHMP to draw conclusions on how well Symbioflor 2 works and whether it is effective for any particular type of IBS, the CHMP has asked the company to carry out a well-designed study on effectiveness and safety among patients with different features of IBS (e.g. those with diarrhoea or with constipation as an important feature). Submission of the study report to national authorities will be a condition for maintaining Symbioflor 2’s marketing authorisation.
The company that markets Symbioflor 2 did not submit data to support its use in ‘functional gastrointestinal disorders’ and agreed to remove this use from the medicine’s authorisation.
The CHMP recommendation will now be sent to the European Commission for a legally binding decision that will be valid throughout the EU.
|EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome||(English only)||23/06/2017|
Latest News from
Tick and flea control agent Bravecto continues to be acceptably safe to use18/08/2017 13:20:00
New adverse reaction to be included in package leaflet
Trend of converging working time across 28 EU Member States has stalled18/08/2017 12:20:00
The difference in working time between workers in the 28 EU Member States remains large and is especially marked between the ‘older’ 15 EU Member States and the 13 new Member States that joined the EU since 2004, according to new research from Eurofound.
European Solidarity Corps: First volunteers in Italy to help rebuild earthquake-hit regions18/08/2017 11:20:00
The first group of European Solidarity Corps volunteers is arriving in Norcia, Italy, to help with the ongoing efforts to repair damage and rebuild social services for the local community affected by the severe earthquakes that hit the region a year ago.
Consultation on CRA Endorsement Guidelines17/08/2017 13:05:00
The European Securities and Markets Authority (ESMA) has published the responses received to its Consultation on Update of the guidelines on the application of the endorsement regime under Article 4(3) of the CRA Regulation.